Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Caitlin Truesdale

CT colleges launch data science programs

Connecticut colleges are launching data science programs to train a new generation of analytics workers. The University of Connecticut’s board of trustees recently approved a...

| By Caitlin Truesdale

Wearable COVID-19 detector from Yale samples air

A team of Yale scientists and engineers has developed a wearable COVID-19 detector that samples the air for the virus and can alert users to an exposure. The...

| By Caitlin Truesdale

Rallybio heads into the clinic

Since Rallybio launched in 2018, the Connecticut-based company has been laser-focused on the development of “transformative therapeutics” for patients suffering from rare and ultra-rare diseases. The leadership...

| By Caitlin Truesdale

Benefits of MDMA – the Drug in Ecstasy – re PTSD

MDMA (3,4-methylenedioxymethamphetamine) is an active ingredient in the illicit street drug known as ecstasy or molly. People in dance clubs and raves use illicit MDMA...

| By Caitlin Truesdale

Weekly Roundup – January 13, 2022

Read the full article in your browser here. Insperity, a small business consultant for more than 30 years, provides an array of human resource solutions...

| By Caitlin Truesdale

Biohaven and Belgium’s KU Leuven in licensing deal

Biohaven acquired exclusive global rights to develop and sell a novel pain drug from Belgium’s KU Leuven university, the New Haven biotech reports. The deal involves...

| By Caitlin Truesdale

Arvinas to double workforce after Pfizer deal

Arvinas recently signed a blockbuster $2.4 billion deal with Pfizer. The bankroll will fund additional trials of the Arvinas breast cancer drug, alone and in combination...

| By Caitlin Truesdale

Career Newsletter – January 11, 2022 

Read the full email here.   Welcome to BioCT’s first Career Newsletter! You can expect an issue every other Tuesday. This is your resource for all career related...

| By Caitlin Truesdale

Rallybio outlines expected milestones for 2022

Rallybio has provided an update on recent accomplishments and announced expected upcoming milestones. “Our mission is to build Rallybio into a leading biotechnology company, with a...

| By Caitlin Truesdale

Biohaven closes migraine-drug deal with Pfizer

Biohaven reports it has completed its transaction with Pfizer to sell the migraine drugs rimegepant and zavegepant outside of the U.S. The deal — potentially worth $1.24 billion...